Immunotherapy spinout Annexon Biosciences collected funding from Novartis Venture Fund in a series C round that brought its total funding to $154m.

Annexon Biosciences, a US-based immunotherapy developer spun out from Stanford University, closed a $75m series C round on Wednesday backed by Novartis Venture Fund, the corporate venturing vehicle for pharmaceutical firm Novartis.
Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital, led the round, which included Surveyor Capital, Adage Capital Partners, New Enterprise Associates (NEA), Satter Investment Management and Blackstone Life Sciences, a subsidiary of investment firm Blackstone.
Founded in 2011, Annexon is an immunotherapy developer…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?